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Abst ract
Ornithine transcarbamylase (OTC) deficiency, an X-linked,
semidominant disorder, is the most common inherited de-
fect in ureagenesis, resulting in hyperammonaemia type II.
The OTC gene, localised on chromosome X, has been map-
p ed to band Xp21.1, proximate to the Duchenne muscular
dystrophy (DMD) gene. More than 350 different mutations,
including missense, nonsense, splice-site changes, small de -
letions or insertions and gross deletions, have been describ -
ed so far. Almost all mutations in consensus splicing sites con-
fer a neonatal phenotype. Most mutations in the OTC gene
are ‘private’ and are distributed throughout the gene with
a paucity of mutation in the sequence encoding the leader
peptide (exon 1 and beginning of exon 2) and in exon 7. They
have familial origin or occur de novo. Even with sequencing
of the entire reading frame and exon/intron boundaries, only
about 80% of the mutations are detected in patients with pro-
ven OTC deficiency. The remainder probably occur within
the introns or in regulatory domains. The authors present 
a 4-year-old boy with the unreported missense mutation
c.802A>G. The nucleotide transition leads to amino acid
substitution Met to Val at codon 268 of the OTC protein.
Key words: novel mutation c.802A>G in exon 8, ornithine
transcarbamylase deficiency, brain spectroscopy, children.
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St reszc zenie
Niedobór transkarbamylazy ornitynowej (OTC), dziedzi-
czony w sposób sprzê¿ony z chromosomem X, to najczêstsza
jednostka chorobowa ureagenezy, stanowi¹ca hiperamonemiê
typu II. Gen OTC zlokalizowany jest w obrêbie chromoso-
mu X, zmapowany w rejonie Xp21.1, proksymalnie do genu
dystrofii miêœniowej Duchenne’a (gen DMD). Do chwili
obecnej opisano ponad 350 ró¿nych mutacji typu zmiany sen-
su, braku sensu, zmiany ramki odczytu czy ma³ych delecji lub
insercji albo du¿ych delecji. Prawie wszystkie mutacje zwi¹ -
zane ze zmian¹ ramki odczytu wywo³uj¹ fenotyp noworod-
kowy. Wiêkszoœæ mutacji w genie OTC to mutacje prywatne
z dystrybucj¹ w obrêbie ca³ego genu oraz z brakiem mutacji
w sekwencji koduj¹cej g³ówne bia³ko (egzon 1 lub pocz¹tek
egzonu 2) i w egzonie 7. Maj¹ one pochodzenie rodzinne lub
pojawiaj¹ siê de novo. Sekwencjonowanie ca³ej ramki odczy-
tu oraz granic egzon/intron pozwala na wykrycie 80% muta-
cji u pacjentów z rozpoznanym OTC. Pozosta³e mutacje praw-
dopodobnie wystêpuj¹ w obrêbie intronów lub domen
regulatorowych. Autorzy prezentuj¹ przypadek 4-letniego
ch³opca z nieopisan¹ mutacj¹ typu zmiany sensu c.802A>G.
Przemieszczenie nukleotydów prowadzi do zamiany metio-
niny na walinê w kodonie 268 bia³ka OTC.
S³owa kluczowe: nowa mutacja c.802A>G w egzonie 8, deficyt
transkarbamylazy ornitynowej, spektroskopia mózgu, dzieci.
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Introduction
Ornithine transcarbamylase (OTC) deficiency, an
X-linked, semidominant disorder, is the most common
inherited defect in ureagenesis, resulting in hyperam-
monaemia type II. Incidence of this metabolic disorder
is estimated as 1 : 80 000 live births in the Japanese
population [1,2]. The OTC gene, localised on chromo-
some X, has been mapped to band Xp21.1, proximate
to the Duchenne muscular dystrophy (DMD) gene.
More than 350 different mutations have been described
so far [3]. Almost all mutations in consensus splicing
sites confer a neonatal phenotype. Most mutations in
the OTC gene are ‘private’ and are distributed through -
out the gene with a paucity of mutation in the sequence
encoding the leader peptide (exon 1 and beginning of
exon 2) and in exon 7 [1,3-5]. They have familial ori-
gin or occur de novo. Even with sequencing of the entire
reading frame and exon/intron boundaries, only about
80% of the mutations are detected in patients with pro-
ven OTC deficiency. The remainder probably occur
within the introns or in regulatory domains [1,3].
The OTC gene is expressed in the liver and in the
mucosa of the small intestine [1]. A deficit of this enzy-
me results in disturbed incorporation of ammonia into
the cycle of transformations, leading to urea synthesis,
which, consequently, results in hyperammonaemia.
A part of the cycle of transformations takes place in the
mitochondrial matrix; thus, any disorders of mitochon-
drial functions may reduce urea production.
Clinical symptoms of hyperammonaemia include,
regardless of its cause, a lack of appetite, irritability, respi-
ratory disorders (heavy or rapid breathing), vomiting,
apathy, coma, somnolence, and cerebral oedema. The fol-
lowing symptoms are seen in the neonatal period with the
onset usually on the second day of life: aversion to suc-
king, intermittent agitation and apathy, vomiting, tachyp-
noea, respiratory alkalosis, apnoea, convulsions and hypo-
thermia, frequent intracranial haemorrhages, death of
neonates without diagnosis in the medical history of the
family [1]. The clinical picture of the patients is extre-
mely variable. Male hemizygotes are usually severely
affected during early childhood, while in heterozygotes
the course of the disease may be milder or asymptomatic.
About 15% of heterozygous females have life-threatening
hyperammonaemic comas. Both symptomatic and asymp-
tomatic carriers show increased orotic acid extraction,
especially under the protein loading test [6].
The diagnosis of OTC deficit is based on identifi-
cation of hyperammonaemia, in chromatographic par-
tition of amino acids, hypocitrullinaemia and increased
levels of glutamine, alanine and lysine, in the course of
acute disorders, and increased excretion of orotic acid
in urine is a characteristic feature [1,3]. The diagnosis
is confirmed by measuring the enzyme activity in biop-
sy of the liver or the intestine coupled with molecular
diagnostics.
In the differentiation process, the following factors
should, among others, be taken into account: other pri-
mary hyperammonaemias and secondary ones – orga-
nic acidurias, disorders of fatty acid oxidation and mito-
chondrial cytopathies.
In this report we describe a 4-year-old patient with
clinical manifestations of hyperammonaemia type II.
The diagnosis was proved by biochemical and molecu-
lar tests that revealed a novel mutation of the OTC gene
in the patient and his mother.
Case report
The case concerns a 4-year-old boy, a son of young,
healthy and unrelated parents, a child from the first pre-
gnancy, born on time by spontaneous delivery, with
a birth weight of 2800 g, and Apgar score of 10 points.
The family history includes death of an infant in the
mother’s family. The psychomotor development was nor-
mal. From the tenth month of life symptoms of decom-
pensation reoccurred, with vomiting and behavioural
disorders (with intermittent apathy or agitation), most
often preceded by an infection of the upper respiratory
tract with fever.
In additional examinations, performed in periods of
metabolic decompensation, elevated activities of amino-
transferases and creatinine kinase (CK) were found:
AspAT (aspartate transaminase) 400 U/l; ALAT (ala-
nine transaminase) 300 U/l; CK 600 U/l. In the tenth
month of life, hepatitis was suspected but infection with
HBV (hepatitis B virus), HCV (hepatitis C virus), CMV
(cytomegalovirus) or Toxoplasma gondii was excluded.
At the age of 18 months, the patient was referred to
diagnostics with suspected muscular dystrophy because
of periodically occurring weakness of lower limbs and
frequent falls. In physical examination no abnormalities
were found, while neurological examination revealed
muscular hypotonia with preserved tendon reflexes, and
hypertrophy of calves. Developmental quotient (DQ)
= 82 (assessed according to the Brunet-Lezine scale). In
additional studies: CK 1830 U/l, serum lactate 3.5 mmol/l.
Organic acids in urine by the GC/MS (gas chromato-
graphy mass spectrometry) method showed dicarboxy-
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lic aciduria without ketosis. The results of other studies
(blood cell counts, aminotransferases, glycaemia, ammo-
nia, urea, creatinine, orotic acid in urine, serum amino-
gram, the profile of acylcarnitines) were normal.
Magnetic resonance imaging (MRI) of the head did
not reveal abnormalities. Electromyography and ultra-
sonography of abdominal organs were normal.
In the 22nd month of life, in the course of an infec-
tion of the upper respiratory tract with fever, the child’s
condition rapidly deteriorated: vomiting was observed,
with general weakness, and growing quantitative con-
sciousness disturbances. In physical examination, an
infection of the upper respiratory tract was confirmed.
Neurological examination revealed generalised muscu-
lar hypotonia with maintained tendon reflexes. Additio-
nal examinations showed: ALAT 2046 U/l, AspAT
3789 U/l, CK 1271 U/l, lactic acid 4.2 mmol/l, ammo-
nia in serum 146 mmol/l, serum aminogram – increased
concentrations of alanine, asparagine and glutamate,
citrulline concentration below detectability level, orotic
acid in urine – 229 µg/µmol creatinine (control value
< 3 µg/µmol of creatinine), organic acids in urine by
the GC/MS method – orotic aciduria was found, asso-
ciated with hyperammonaemia. In computed tomogra-
phy (CT) of the head, calcifications were identified in
subcortical nuclei. Electromyography was abnormal,
with features of a myopathic pattern.
On the basis of the clinical picture and the results of
performed studies, a suspicion of urea cycle disorders –
hyperammonaemia type 2 – was postulated. The diag-
nostics were then extended towards OTC deficiency –
a protein load test and a test with allopurinol, performed
in the mother (for identification of heterozygotes), result-
ed in normal results. Subsequent episodes of general
condition breakdown – metabolic crises, induced by
infection of the upper respiratory tract – took place at
the age of 2.5 and 3.5 years.
Magnetic resonance spectroscopy measurements
At the age of 4 years, nuclear magnetic resonance
measurements were done using the whole-body 2T mag-
netic resonance imaging/magnetic resonance spectro -
scopy (MRI/MRS) system operating at a proton reso-
nance frequency of 81.3 MHz. Four voxels of 1.5 ×
1.5 × 1.5 cm3 were localized using the PRESS (point
resolved in vivo spectroscopy) sequence (TR 1500 ms,
TE 35 and 136 ms and 100 acquisitions) on bilateral
subcortical nuclei and bilateral dorsolateral prefrontal
white matter regions. Water suppression was achieved
with the help of CHESS (chemical shift selective) puls-
es. The spectra were normalized to 1 within the range
0.0-4.2 ppm. 1H MRS (proton magnetic resonance
spectroscopy) was done in a stable condition, when the
child was treated with a protein restriction diet. During
the last metabolic crisis the child was in a bad condition
and anaesthesia was contraindicated.
The metabolite ratios were obtained using the user-
independent method of spectra analysis [7,8]. N-acetyl -
aspartate (NAA), choline (Cho), creatine and phospho -
creatine (tCr), myo-inositol (mI), glucose (Glc),
glutamine and glutamate (Glx), and lipids and lactate
(LacLip) integral intensities were calculated.
Magnetic resonance spectroscopy showed a dec -
reased value of the NAA/tCr ratio in all areas, and the
Cho/NAA ratio was increased, which confirmed re -
duced NAA (a neuronal marker) (Fig. 1A). In all the
spectra, there was an intensive strip, derived from lipids,
lactate and macromolecules, which is reflected in the
high values of the LacLip/tCr ratio (Fig. 1B).
The Cho/tCr values in the subcortical nuclei were
normal; in the frontal white matter, however, the tCr sig-
nal was reduced, which implies artificially increased
Cho/tCr ratios. The mI/tCr values were markedly re -
duced in the subcortical nuclei, whereas the correspond -
ing values measured in the frontal lobes were normal,
but when taking into account the lower integral inten-
sity of the tCr signal in this area, the mI/tCr values seem
to be overestimated (Figs. 1B and 2).
The Glx/tCr ratios exceeded the normal values in
both the frontal lobes (Fig. 2); however, a reduction of
the tCr peak may be of importance.
Another remarkable finding was the increase of the
broad peak intensities at 0.8-1.5 ppm in the frontal lobes
spectra, which can be assigned to the lipid/lactate com-
plex. Although it is difficult to differentiate lipid with
lactate clearly in the short echo-time proton MR spec-
tra, most of the broad peak intensities at 0.8-1.5 ppm
may be contributed from increased mobile lipids with-
in the investigated regions.
Molecular analysis
To confirm the clinical diagnosis of hyperammona-
emia type II, molecular analysis of the OTC gene was per-
formed in the patient and his mother. Genomic DNA was
isolated from peripheral blood samples and 10 coding
exons of the OTC gene were screened for mutation using
the PCR-SSCP (polymerase chain reaction-single strand
conformation polymorphism) and sequencing analysis.
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The sequence of the shifted fragments (exon 8) was com-
pared with the OTC cDNA sequence (Gene Bank Ref -
Seq: NM_000531) and OTC protein sequence (Gene
Bank NP_000522).
The patient and his mother were shown to carry
a heretofore unreported missense mutation, c.802A>G.
This nucleotide transition leads to amino acid substitu-
tion Met to Val at codon 268 of the OTC protein (Fig. 3).
Based on the protein sequence alignment, Met268 appe-
ars to be the most conserved amino acid located in pro-
tein region SMG, having 100% homology in all studied
organisms, and is thought to be critical for enzyme acti-
vity [8]. The c.802A>G mutation was not detected in
40 control DNA samples, indicating that this allele is
not a common polymorphism (data not shown).
Observation of muscular hypotonia and a high CK
value prompted us to perform molecular analysis of the
DMD gene. No deletion in any fragment of the gene
was found. However, presence of a point mutation was
not excluded.
Discussion
Ornithine transcarbamylase deficiency is one of the
most frequent causes of genetically determined liver
encephalopathy. It is assumed that in liver encephalo-
pathy, the blood-brain barrier is injured, increasing its
permeability not only to ammonia, but also to aromatic
amino acids and to γ-aminobutyric acid (GABA) [9,10].
The cause of increased permeability has not yet been
completely explained; it is assumed that it may be asso-
ciated with impaired transporting mechanisms of capil-
Right thalamus
Left thalamus
Thalamus, normal spectrum
tCr reduction
NAA reduction
Lipids 
and lactate
Fig. 1. Comparison of the 1H MRS (TE = 35 ms) spectra acquired from the patient’s frontal lobes and thalamus, and the spectra obtained from the respective loca-
lizations in the healthy patient at a similar age
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Fig. 2. The Glx/tCr ratios exceeded the normal values in both the frontal lobes.
According to order of appearance: left frontal lobe, right frontal lobe; left tha-
lamus, right thalamus, frontal lobes (normal), thalamus (normal)
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lary vessels, especially those acting in pinocytosis of
astrocytes.
Ammonia is the main substance with neurotoxic acti-
vity; however, methionine, mercaptans, β-hydroxyl deri-
vatives of biogenic amines and short-chain fatty acids
may also take part in the pathogenesis of hepatic ence-
phalopathy [9]. It is supposed that these substances, by
disturbing the activity of membrane ATPase (adenosine
triphosphate), damage the membrane transport of neu-
rons and their energetic metabolism. Ammonia disturbs
mainly the metabolism of glutaminic acid by suppressing
the activity of glutamine synthetase. Both these proces-
ses, combined with the abnormal metabolism of gluco-
se, lead to energetic disorders in the neurons.
The increased permeability of the blood-brain bar-
rier to aromatic amino acids, caused by hyperammona-
emia, changes their proportion in the CNS to the amino
acids with branched chains, causing an intensification of
the synthesis of the so-called false neurotransmitters (tyra-
mine, octopamine and phenylethanolamine) [10].
Another significant mechanism considered in the
pathogenesis of liver encephalopathy is the blockade of
the benzodiazepine receptor by γ-aminobutyric acid,
which disturbs the balance between the systems of
GABAergic and glutaminergic transmitters [9,10].
The results of liver tests and ammonia concentration
do not always correspond with the degree of liver ence-
phalopathy. MRI imaging, performed in the initial sta-
ges of the disease, may not show any abnormalities in
brain structures. In such a case MRS, as a sensitive dia-
gnostic tool providing insight into the biochemistry of
the brain, may be especially useful. In MRS examina-
tions of patients with liver encephalopathy a triad of
symptoms is usually found: increased concentration of
glutamine/glutaminic acid, decreased level of myo-ino-
sitol and choline and, initially, normal concentrations of
NAA. In the studied case only one of the mentioned
typical spectral characteristics is present – the reduced
mI/tCr ratio. Additional findings are reduced NAA and
the increased lipid/lactate complex at 0.8-1.5 ppm deri-
ving from increased mobile lipids within the investiga-
ted regions. It seems unlikely that this latter finding is
caused by fat contamination from the scalp or bone mar-
row because it was observed even in the spectra obta-
ined from the subcortical nuclei, where the volume of
interest was far from the scalp or bone marrow fat. We
speculate that the increase of mobile lipids may be cau-
sed by neuroglial cell membrane damage or disintegra-
tion due to severe metabolic stress, and may be a sign
foretelling brain damage.
A reduction of the cerebral NAA concentration is com-
monly understood as a reduction of neuroaxonal cellular
density and/or dysfunction. In this study NAA loss is espe-
cially marked in the frontal lobes, indicating neuronal/
axonal damage. The observed total creatine pool loss seen
in the frontal lobe white matter is another indicator of cel-
lular disintegration. Total creatine is often used as an inter-
nal standard assuming that its level is constant in the brain.
However, the creatine levels can vary according to the
nature of clinical diseases, and the lowering of the tCr sig-
nal may represent a cerebral energy deficit [1].
Under the effect of increased ammonia concentra-
tion in the brain, the synthesis of glutamine in astrocy-
tes is usually enhanced as well as glutamine storage [9].
These are the only cells in the central nervous system
(CNS) with glutamine synthesis ability, this reaction
Fig. 3. Sequencing of the OTC gene showing the c.802A>G (p.Met268Val)
mutation in exon 8 in the patient and his mother
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being the chief means of ammonia elimination from the
nervous system. One may speculate that the increased
glutamine accumulation triggers a compensatory decre-
ase in myo-inositol since both these compounds exert an
osmoregulatory function. Such an effect has been descri-
bed for cultured astrocytes [10].
However, the Glx levels seem to be normal in this
study (only an artificial increase due to the total creatine
loss is observed within the frontal lobes). Since myo-
inositol is considered to be an astrocyte marker, a dec -
reased myo-inositol level may alternatively indicate
a lower number of astrocytes rather than a compensa-
tion for glutamine increase [11]. In the case of a drastic
reduction of the number of astrocytes vs. neurons, a sig-
nificant decrease in creatine should be expected and, in
fact, its signal at 3.03 ppm is drastically low in the frontal
white matter MRS spectra of the studied subject. No
correlation was found between the level of myo-inositol
and the degree of hepatic encephalopathy; thus it is sug-
gested that other, osmotically active substances, such as
taurine and betaine, may play some role in the process
as well. Changes in the myo-inositol and choline con-
tent and often normal level of NAA in patients with liv-
er encephalopathy indicate that this pathology is, first of
all, a result of oedema and disturbed function of astro-
cytes without any damage to neurons.
The outcomes of MRS studies confirm the theories
that, in liver encephalopathy, there are disorders in neu-
rotransmission, especially at the level of the junction of
glial cells and neurons. The observed changes in choli-
ne concentration have not yet been explained. It is sug-
gested that they may result from disorders of transport,
metabolism or absorption from the gastrointestinal tract.
The increased perfusion of basal ganglia makes them
more susceptible to the effects of metabolic disorders.
In neuroimaging studies, hyperintensity, especially of
the globus pallidus, was observed.
In liver encephalopathy, the cerebral metabolism of
glucose is significantly disturbed, together with incre-
ased lactate concentration, which results from decreased
oxidation of pyruvate and enhanced synthesis from glu-
cose. The increased concentration of lactate in the CNS
causes an increase in intracranial pressure.
One of the hypotheses assumes that liver encepha-
lopathy may be induced by disturbed function of astro-
cytes, resulting from changes of expression of genes
encoding for proteins, the changes caused by hyperam-
monaemia. It further results in transport disorders and
elimination of glutaminic acid, glycine, glucose and
monoamines.
The most important issue in this case report is that
the patient escaped from the diagnostics for such a long
time. Despite the fact that previous episodes suggested
metabolic dysfunction of the CNS, the first abnormal
ammonia level was confirmed when the child was almost
two years old. Probably the former measurements were
within the normal range because during the crises the
child received intravenous replacement of fluids in the
local hospitals. After the recommendation of taking
a blood sample before the intravenous treatment, hyper -
ammonaemia was observed.
The identified substitution c.802A>G in exon 8
(p.Met268Val) is a novel mutation, being one of over
350 different mutations in the OTC gene reported to date.
The mutation results in replacement of methionine 268
by a valine residue. According to Tuchman et al. [8] 
exon 8 contains many conserved nucleotides (particu-
larly in codons 263, 267 and 268), which code the ami-
no acids forming the enzyme active site. The mutation
identified in the Polish family is therefore highly likely
to be disease causing. The pathogenic, not polymorphic
character of the mutations is firmly supported by the
absence of p.Met268Val substitution in any of 80 fami-
lies with OTC deficiency and in 20 control females.
The substitution p.Met268Val, like the described
mutation Met268Thr in the same amino acid position,
produces a mild phenotype of OTC deficiency termed
‘late-onset’ hyperammonaemia. Morizono et al. [12]
analysed some patients with mild disease phenotype and
the mutation Arg277Trp, located in exon 8 in a 9 amino
acid residue loop remote from the active site. Compared
to the wild type, Arg277Trp mutant protein had nearly
70-fold lower affinity for L-ornithine, one of two sub-
strates of OTC enzyme, and characterized by reduced
thermal stability. It may be predicted that mutated pro-
tein with Met268Val substitution will also present
reduced affinity for L-ornithine and lower activity of the
OTC enzyme.
Molecular analysis in the asymptomatic proband’s
mother revealed the presence of the same nucleotide sub-
stitution c.802A>G on one OTC gene allele. Despite
this, an allopurinol loading test showed no elevated oro-
tic acid level and resulted in no identification of the dise-
ase-carrier status of the woman. Our observation of the
normal orotic acid level in the allopurinol loading test
in the patient’s mother, along with the identified OTC
gene mutation, supported the probability of undefined
or false negative results reported previously for hetero-
zygous females [13-17]. Direct mutation analysis of the
OTC gene is therefore important for providing accura-
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te carrier detection and prenatal diagnosis in OTC defi-
ciency families.
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